Stage III Verrucous Carcinoma of the Larynx Completed Phase 1 Trials for DB00530 (Erlotinib)

IndicationStatusPhase
DBCOND0029516 (Stage III Verrucous Carcinoma of the Larynx)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00049283Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck CancerTreatment